Research note · Metabolic health · Glycemic control
Bergamot vs Metformin:
What the Evidence Actually Shows
Editorial disclaimer: EOS Research summarizes published research for educational purposes. This is not medical advice. Bergamot is a food ingredient, not an approved diabetes treatment. Consult a physician before making any changes to medication or supplementation.
Who this is for: This editorial is written primarily for metabolically healthy adults interested in healthspan optimization — not for individuals taking metformin to treat diabetes. Recommendations differ substantially between those populations.
Contents
The claim
A circulating video claims that "according to studies, bergamot has as much power as metformin" for blood sugar control. It's the kind of statement that sounds plausible — bergamot is studied for metabolic health — and the kind that deserves a careful look before it spreads further.
This note examines what the evidence actually says, what it doesn't say, and where the gap between mechanism and efficacy sits.
What bergamot does — three pathways
Bergamot (Citrus bergamia) is a citrus fruit whose polyphenol-rich fraction has been studied for metabolic effects. Our review of the literature identified 64 papers connecting bergamot to glucose metabolism, diabetes, or insulin — and three distinct mechanisms of action.
1. AMPK activation — shared with metformin
A 2023 double-blind, placebo-controlled trial confirmed that a standardized bergamot extract (Brumex™) stimulates phosphorylation of AMP-activated protein kinase (AMPK) at threonine 172 — the same activation site targeted by metformin.1 The same study measured significant reductions in fasting plasma glucose in 50 moderately hypercholesterolemic subjects over 12 weeks, alongside improvements in lipids and liver enzymes.
This is not an isolated finding. Earlier work (2019) demonstrated that a flavonoid-rich bergamot juice extract activates the AMPK/SIRT1 axis in cell-free and in vitro models,2 and a 2019 review consolidated evidence that bergamot polyphenols alter AMPK function.3
2. GLP-1 receptor signaling — shared with Ozempic class
A 2026 in vitro study found that a phospholipid-formulated bergamot extract exhibited dose-dependent GLP-1 receptor-associated signaling, reaching approximately 60% of the response of a positive control (GLP-1R agonist II).4 This is the same receptor targeted by semaglutide (Ozempic, Wegovy) and other GLP-1 agonists.
This is in vitro evidence only — measured in a U2OS cell line expressing cAMP-sensitive biosensors. No human data exists on bergamot's GLP-1 activity. Notably, the same study found no effect on DPP-4 activity or GLUT-4-mediated glucose uptake, suggesting the GLP-1R pathway is the primary mechanism under investigation rather than a broad-spectrum effect.
3. GLUT-4 expression and insulin signaling
A 2026 animal study using a metabolic syndrome rat model found that powder bergamot juice increased total protein expression of glucose transporter type 4 (GLUT-4) in skeletal muscle and attenuated insulin resistance.5 A 2025 rat study of bergamot leaf extract showed significant improvement in insulin resistance scores (IR-HOMA from 6.91 to 3.79, p < 0.001).6
Here's where it gets interesting
Bergamot appears to work through three distinct glucose-regulating pathways: AMPK (shared with metformin), GLP-1R (shared with Ozempic), and GLUT-4 upregulation. Multi-mechanism activity is unusual for a plant compound and deserves serious investigation. But mechanism is not the same as outcome.
What metformin does — for comparison
Metformin is the most prescribed diabetes drug in the world, with thousands of randomized controlled trials spanning 60+ years of use. Its primary mechanism is AMPK-mediated suppression of hepatic glucose production (gluconeogenesis), with secondary effects on insulin sensitivity and gut glucose absorption. Typical HbA1c reduction: 1.0–1.5%.
The longevity question is a separate conversation. The TAME (Targeting Aging with Metformin) trial, designed to test whether metformin can delay multiple age-related diseases in older adults, is ongoing. Until those results are available, longevity claims for metformin in healthy adults remain hypotheses, not established clinical facts.8 A major 2025 review in Ageing Research Reviews concluded that enthusiasm for metformin as an anti-aging drug has weakened, as many early observational findings have not held up in better-controlled studies or trials involving healthy adults.8
No study of any kind has compared bergamot to metformin head-to-head. The comparison is indirect at best.
Evidence hierarchy
| Claim | Metformin confidence | Bergamot confidence |
|---|---|---|
| Lowers blood glucose | ⭐⭐⭐⭐⭐ | ⭐⭐⭐☆☆ |
| Improves lipid profile | ⭐⭐⭐⭐☆ | ⭐⭐⭐⭐☆ |
| Reduces cardiovascular events | ⭐⭐⭐⭐⭐ | ⭐☆☆☆☆ |
| Anti-inflammatory effects | ⭐⭐⭐☆☆ | ⭐⭐⭐☆☆ |
| Extends lifespan (healthy humans) | ⭐⭐☆☆☆ | ⭐☆☆☆☆ |
The human data gap
The evidence for bergamot's glucose-lowering effect in humans rests on two small randomized controlled trials:
- Mollace et al. (2019): 60 patients with type 2 diabetes and mixed hyperlipidemia. Bergamot polyphenolic fraction (BPF) significantly reduced fasting plasma glucose, LDL cholesterol, and triglycerides. HbA1c was not reported.7
- Pierdomenico et al. (2023): 50 moderately hypercholesterolemic subjects. Bergamot extract (Brumex™) significantly reduced fasting plasma glucose among other metabolic markers. Primary endpoint was lipids, not glucose.1
Both studies show statistically significant glucose reductions — but "significant" in these contexts means statistical significance, not clinical significance comparable to a diabetes drug. Neither study reports HbA1c, which is the standard metric for glycemic efficacy in diabetes research.
For context: metformin's glucose-lowering effect is established across hundreds of trials enrolling thousands of patients, with HbA1c reduction as the primary endpoint. Bergamot's evidence base is approximately 110 patients total, none measured on HbA1c.
Publication pattern
A significant portion of bergamot metabolic research comes from the University "Magna Graecia" of Catanzaro research group (Mollace et al.), often in collaboration with Indena S.p.A., a supplement ingredient manufacturer. This is not a dismissal of the research — the studies are well-designed for their size — but it is a concentration caveat similar to the BPC-157 literature.
What we don't know
- No head-to-head comparison with metformin. The central claim of the video cannot be evaluated because the experiment has never been done.
- No HbA1c data. All human bergamot studies report fasting plasma glucose. HbA1c — the standard measure of glycemic control over 2-3 months — is absent.
- GLP-1R finding is in vitro only. The 2026 study was in a cell line. Whether this translates to human GLP-1 secretion or receptor activation in vivo is unknown.
- Sample sizes are small. Total human evidence across all glucose-related bergamot RCTs: approximately 110 patients.
- Duration is short. The longest published trial is 12 weeks. Diabetes is a chronic condition managed over years.
- No safety data for chronic use in diabetes. Bergamot is Generally Recognized as Safe (GRAS) as a food ingredient. Long-term safety data at therapeutic doses for glycemic control does not exist.
- Bergamot-metformin interaction not studied. Using both together may further lower blood glucose and warrants medical supervision, particularly in people with diabetes. Evidence for this interaction is theoretical or based on limited data, but the risk is worth acknowledging.9
- Bergamot-drug interactions unknown. Bergamot is known to inhibit CYP3A4 (the grapefruit effect). How this interacts with diabetes medications has not been studied.
The insight
Three mechanisms, 110 patients, zero head-to-head trials.
Bergamot's multi-pathway activity (AMPK + GLP-1R + GLUT-4) is genuinely interesting and unusual for a plant compound. The mechanistic evidence is stronger than I initially expected — bergamot does share pathways with both metformin and Ozempic at the cellular level.
But the human data is too thin to support an efficacy claim. The gap between "activates AMPK in a cell" and "controls diabetes as well as metformin" is wide, and no study has attempted to cross it.
The reported preclinical signals are extensive. The confident human claims are unsupported.
Evidence Scorecard
| Domain | Metformin | Bergamot |
|---|---|---|
| Human evidence (RCTs) | A | B− |
| Mechanistic evidence | A | A− |
| Long-term safety | A | B+ |
| Longevity evidence (healthy humans) | C | D |
| Recommendation confidence | High (for diabetes) | Moderate (for metabolic support) |
References
- Pierdomenico M, Cicero AFG, Veronesi M, et al. Effect of Citrus bergamia extract on lipid profile: A combined in vitro and human study. Phytother Res. 2023;37(9):4185-4195. PMID: 37312672
- Ferlazzo N, Visalli G, Smeriglio A, et al. The link between the AMPK/SIRT1 axis and a flavonoid-rich extract of Citrus bergamia juice: A cell-free, in silico, and in vitro study. Phytother Res. 2019;33(7):1852-1862. PMID: 31094018
- Mollace V, Gliozzi M, Carresi C, et al. Clinical application of bergamot (Citrus bergamia) for reducing cardiovascular risk. Integr Food Nutr Metab. 2019;6(3). PMID: 31057945
- Khan A, Mella RM, Villacé P, et al. In Vitro Evaluation of GLP-1R-Associated Activity of a Sustainable Standardized Phospholipid-Formulated Bergamot Extract. Biomedicines. 2026;14(5):1111. PMID: 42193436
- Musolino V, Gliozzi M, Carresi C, et al. Powder bergamot juice attenuates skeletal muscle complications in an experimental model of metabolic syndrome. Mol Cell Endocrinol. 2026;587:112213. PMID: 42142734
- Russo R, Marra F, Mollace R, et al. Anti-inflammatory effect of bergamot leaves extract attenuates cardiac remodeling in obese rats. PLoS One. 2025;20(1):e0316710. PMID: 41134766
- Mollace V, Scicchitano M, Paone S, et al. Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study. Endocr Metab Immune Disord Drug Targets. 2019;19(2):136-143. PMID: 30501605
- Newman JC, Kimmel SE, Barzilai N, et al. Targeting Aging with Metformin (TAME): study design and methods. Innov Aging. 2024;8(Suppl 1):1168. See also: Ageing Res Rev. 2025;93:102147.
- Bergamot-metformin interaction: limited case reports and theoretical risk based on CYP3A4 and glucose-lowering synergy. HelloPharmacist review